

Rubicon Research acquires its first US Manufacturing Facility

22 July 2026

Rubicon Research Limited (“Rubicon” or the “Company”) today announced the acquisition of a manufacturing facility in East Brunswick, NJ from InvaTech Pharma Solutions, LLC (“InvaTech”) at an enterprise value of USD 2.9 million. As part of the transaction, Rubicon has taken over the facility including the lease and all equipment, records and permits associated with the site on 21 July 2026. This acquisition gives us a US manufacturing footprint that is about the same size as our facility at Satara and does not include any product approvals or filings.

Rubicon’s wholly owned subsidiary AdvaGen Holdings (“AdvaGen”) emerged the successful bidder in a court-supervised competitive bid process under Section 363 of the U.S. Bankruptcy Code. AdvaGen has also entered into a long-term lease on the site.

This operational facility manufactures oral solid and oral liquid formulations and has been USFDA inspected for over a decade with 3 successful inspections. The USFDA carried out an unannounced inspection of this facility in May 2026. The inspection resulted in a Form 483 issuance with 6 observations that were largely procedural in nature and unrelated to data integrity. Invatech has responded to the Form 483 within the prescribed time and has completed the corrective actions expected by the USFDA, based on which we expect the inspection to be successfully concluded in a timely manner.

This site will focus on Rubicon’s specialty and high value products as well as demand from US government departments. We expect to commence manufacturing our products at the site in calendar year 2027 after completing implementation of our quality management systems.

Commenting on the acquisition, Parag Sancheti, Rubicon’s CEO said *“The ability to manufacture in the US strongly complements our growing portfolio of branded and specialty products. We value the ability to be closer to our customers and the enhanced agility and resilience this facility brings to our global supply chain. In addition to a strong USFDA inspection history, the site shares a wall with our US distribution center operated by our subsidiary AimRx which enables a unique opportunity for efficient expansion. We will make significant capital investments over the next 3 years to expand the breadth and depth of manufacturing capabilities at this facility.”*

About Rubicon Research Limited

Rubicon Research Limited is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of differentiated pharmaceutical products. Established in 1999,



INNOVATION | QUALITY | CARE

Rubicon has evolved from a contract development services organization into an R&D led, vertically integrated pharmaceutical company with capabilities spanning research and development, specialty, branded and generic product commercialization; and manufacturing across multiple dosage forms.

Rubicon currently has a portfolio of 80+ pharmaceutical products across multiple therapeutic areas, including a meaningful portfolio of CNS products. The company operates globally inspected manufacturing facilities in India regulated by authorities including the U.S. Food and Drug Administration, UK MHRA, and Australian TGA. Rubicon also maintains a strong R&D organization of over 200 scientists across development centres in Mumbai and Toronto, reflecting deep formulation expertise and a strong focus on differentiated drug delivery technologies.

Rubicon is a public company, listed on the National Stock Exchange of India and BSE Limited.

Contact Information

Investor Relations:

investors@rubicon.co.in

Rubicon Research Limited (formerly known as **Rubicon Research Private Limited**) | CIN: L73100MH1999PLC119744

Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India
☎ +91-22-61414000 / 50414000 | ✉ reachus@rubicon.co.in | 🌐 www.rubicon.co.in